The American Society of Oncology (ASCO) 2019 Annual Meeting was held in Chicago, IL, from 31 May – 4 June. A world-renowned faculty discussed state-of-the-art treatment modalities, ongoing controversies in the field, and the latest data.

ASCO 2019

31 May–04 June 2019 | Chicago, Illinois

ASCO 2019

31 May–04 June 2019 | Chicago, Illinois

The American Society of Oncology (ASCO) 2019 Annual Meeting was held in Chicago, IL, from 31 May – 4 June. A world-renowned faculty discussed state-of-the-art treatment modalities, ongoing controversies in the field, and the latest data.

Managing myeloma in geriatric patients 1:52
Managing myeloma in geriatric patients
Ashley Elizabeth Rosko
MRD testing in AML: the next steps in 2019 2:36
MRD testing in AML: the next steps in 2019
Michael Heuser
How to utilize MRD testing for AML 2:27
How to utilize MRD testing for AML
Michael Heuser
Managing post-transplant relapse in AML 3:41
Managing post-transplant relapse in AML
Charles Craddock
The clinical application of MRD testing in AML 1:30
The clinical application of MRD testing in AML
Michael Heuser
Treatments to prevent relapse in AML 2:48
Treatments to prevent relapse in AML
Charles Craddock
CLL: Susan O’Brien’s top ASCO 2019 picks 2:27
CLL: Susan O’Brien’s top ASCO 2019 picks
Susan O’Brien • 1 Jun 2019
Second generation BTK-inhibitors for CLL 2:48
Second generation BTK-inhibitors for CLL
Susan O’Brien • 1 Jun 2019
Treating high-risk myeloma in the elderly 1:16
Treating high-risk myeloma in the elderly
Ashley Elizabeth Rosko • 1 Jun 2019
Improving the management of geriatric myeloma 2:40
Improving the management of geriatric myeloma
Ashley Elizabeth Rosko • 1 Jun 2019
MRD: decision making in CLL 3:26
MRD: decision making in CLL
Susan O’Brien • 1 Jun 2019
Characterizing bridging strategies for CAR T-cell therapy 0:59
Characterizing bridging strategies for CAR T-cell therapy
Karlo Perica • 1 Jun 2019
Resonate: Ibrutinib associated with favourable PFS and OS in CLL 1:26
Resonate: Ibrutinib associated with favourable PFS and OS in CLL
Susan O’Brien • 1 Jun 2019
CAR-T for ALL: bridging options and choices 1:00
CAR-T for ALL: bridging options and choices
Karlo Perica • 1 Jun 2019
MRD: venetoclax vs. BTK-inhibitors for CLL 1:30
MRD: venetoclax vs. BTK-inhibitors for CLL
Susan O’Brien • 1 Jun 2019
CAR-T for ALL: the impact of bridging therapy 3:12
CAR-T for ALL: the impact of bridging therapy
Karlo Perica • 1 Jun 2019
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals